Registration is open for the 2024 ASRM Scientific Congress & Expo

Close Close Icon
Ethics Committee teaser

Ethical obligations in fertility treatment when intimate partners withhold information from each other: an Ethics Committee opinion (2024)

Clinicians should encourage disclosure between intimate partners but should maintain confidentiality in cases where there is no prospect of harm to the partner and/or offspring. In cases where a member of a couple refuses to disclose relevant health information to the other partner and there exists a risk of harm to the unaware partner and/or offspring, clinicians may refuse to offer care and should decline to treat if full informed consent is not possible because of the lack of disclosure. This document replaces the previously published document of the same name, last published in 2018. (Fertil Steril® 2024;121:428–33. ©2024 by American Society for Reproductive Medicine.)



  • Physicians should encourage couples presenting for fertility treatment to disclose to one another relevant information that can affect their reproductive decision-making.
  • Ideally, the reproductive dyad should sign a waiver allowing for their physician to share all clinically relevant information with both reproductive partners. This would include information provided by either member of the couple as well as information discovered during evaluation and treatment. The waiver should set forth a clinic’s policy on disclosure of clinically relevant information, including disclosure in the absence of the patient or partner’s further consent. If themembers of the dyad are unwilling to sign thewaiver, physicians should explain any limits to care, including the possibility that theywill be unable to provide care if protecting the confidentiality of 1 partner precludes informed consent on the part of the other partner.
  • Cases may arise in which a patient asks a physician to withhold clinically relevant information from their intimate partner. In such cases, physicians are both ethically and legally bound to maintain patient confidentiality, except as otherwise provided by law.
  • When confidentiality cannot be maintained (e.g., because of state reporting requirements), the patient should be told this, ideally before the information is obtained. In such situations, it is ethically permissible for the physician to decline care.
  • In cases where the lack of disclosure precludes fully informed consent or has the potential to harm the patient, their intimate partner, or their offspring, physicians should strongly encourage disclosure. If the patient declines to allow for such disclosure, physicians are ethically obligated to decline the provision of reproductive care.
  • The lack of information sharing between intimate partners can impede a physician’s ability to obtain fully informed consent from both members of the couple. Potential impacts on informed consent include the physician’s inability to fully discuss the range of possible treatment options as well as the risks and benefits of the proposed treatment. In such cases, physicians may proceed or decline to offer treatment and should make such judgments in a nondiscriminatory fashion and without bias, taking into consideration potential risks to the partner and potential offspring and potential liability risks to the physician if they proceed without being able to obtain fully informed consent.
  • In cases where the information, if disclosed, may be relevant to the partner’s decision whether to undergo fertility treatment, the physician should also strongly encourage disclosure between intimate partners. This includes situations in which fertility treatment is required that could otherwise have been avoided if certain information had been shared.

When couples present for fertility care, they usually do so as a unit whose interests are aligned. Ideally, couples present for evaluation and treatment having already shared relevant information often with one another regarding their  reproductive health and risks. Fertility care providers routinely advise couples that they are equal members of the treatment dyad and encourage open communication and honesty. In fact, several physicians ask that couples allow information to be shared freely between the physician and each of them, even when this information pertains to their partner. As a practical matter, providers should consider requesting that patients with partners sign a waiver of confidentiality regarding all information that is material to the provision of fertility care services. Such a waiver would permit a provider to share relevant information with the couple as needed in the context of the treatment being sought. This would include both information shared by either member of the couple and information that is discovered during the medical evaluation and treatment. If a couple, or a member of a couple, declines to sign such a waiver, physicians may decline to provide treatment on the basis of concerns that fully informed consent cannot be assured.

Situations can arise in which a couple presents to a physician for treatment and a member of the couple shares information with the physician that they ask not to be shared with their partner. In some cases, this information is relevant to the medical management of 1 or both members of the couple and may affect treatment options, outcomes, and risks to the partner or any resulting children. In these cases, the physician may have serious reservations about initiating or continuing treatment for partners who do not disclose to one another. This committee opinion will address various situations that may arise and the responsibility of the physician to each member of the couple individually and to the couple as a whole in such cases.

Physicians have several options when asked by a patient not to disclose pertinent information to the patient’s partner. One is to encourage disclosure but to continue treatment in the absence of disclosure, being careful not to share any information that they have been asked to keep in confidence. The second is to require disclosure between the partners before moving ahead with treatment and to decline to treat a couple if they refuse to share information with each other that the physician judges material to their care. In either case, an emphasis on counseling from a trained mental health professional with expertise in the complex psychosocial issues faced by fertility patients should be offered and encouraged and may help couples feel more comfortable sharing mutually relevant information with one another (1).

When relevant clinical information is not freely shared between intimate partners, this may impact informed consent. The physician’s ability to obtain informed consent from the couple, and particularly from the member of the couple from whom information has been withheld, may be impeded. Such cases prove difficult because physicians may be limited in their ability to explain why a given treatment is not offered, another treatment is recommended, or the recommended treatment is not optimal. Particularly when the lack of disclosure between intimate partners limits the ability to obtain fully informed consent from all stakeholders, free information sharing should be strongly encouraged. Physicians should decline to provide treatment when fully informed consent for the proposed treatment itself cannot be given by both partners because 1 partner would be subjected to risks and treatment options that cannot be disclosed without violating the confidentiality of the withholding partner.

Importantly, in some cases, there may be consequences of disclosure for the safety or well-being of the intimate partner. This is particularly so for individuals who may face violence, abuse, or rejection. As such, disclosure requires great sensitivity and should be accomplished in the manner most preferred by the patient while ensuring that it does not cause
the patient harm.

Several broad categories of harm can occur when intimate partners fail to disclose material information regarding themselves. These will be discussed individually in the following sections. Many of the clinical examples provided in this document focus on communicable diseases because the lack of disclosure of disease status may be preferred by 1 partner but have implications for the reproductive decision-making of the other partner. The intent of these examples is not to stigmatize infectious diseases, which are common among sexually active adults (2). In cases of infectious disease, physicians should be familiar with and abide by state and federal reporting requirements and should make these obligations clear to their patients.


If the provider of the sperm carries an infectious disease, there can be a risk of physical harm to the partner when fertility treatments involve using the infected individual’s sperm. Although strategies exist to lower significantly—and perhaps almost eliminate—transmission of human immunodeficiency virus (HIV), no strategy can guarantee with absolute certainty that disease transmission will not occur (3, 4). Hepatitis C and hepatitis B are other infectious diseases that can be theoretically transmitted through reproductive treatment. It is recommended that screening for infectious disease, when available, be universal and routine, as effective treatments for many exist, and consideration of alternative treatment modalities can prevent transmission to both sexual partners and offspring.

In a previous Ethics Committee opinion (3), the American Society for Reproductive Medicine has taken the position that it is permissible to offer infertility treatment to HIV-infected persons if the clinic has the necessary facilities and the partners are willing to use the recommended methods of risk reduction. In that opinion, the Committee stated: ‘‘Informed consent in the medical setting requires that physicians disclose any information material to a person’s decision to undergo or refuse treatment.’’

By contrast, cases in which donor gametes are used, or in which a female but not the male partner has an infectious disease and artificial insemination is used, do not place the partner at risk of infection. However, a female who carries an infectious disease should be strongly encouraged to disclose this information to her partner given the potential risks of vertical transmission to the offspring as well as transmission to the partner if they are sexually intimate (3). In this situation, clinicians may refuse to provide care because the nongestational parent would not be aware that treatment leading to pregnancy places the offspring at risk of acquiring an infectious disease because this may violate their ability to provide fully informed consent, as detailed in the following section.


A particular example in which a partner may not be able to fully participate in informed consent but does not face any physical risks to themselves is a scenario in which harm to the offspring may occur on the basis of genetic risks that a partner may not wish to share. For example, a woman may know that she is a carrier of an X-linked disorder such as fragile X. She may not wish to disclose the fact that her offspring could be affected by fragile X to her partner. Similar situations arise when one of the partners is a carrier of Huntington disease or breast cancer gene, conferring risk on the children without the knowledge of the other partner. In these situations, the uninformed partner may have made different reproductive decisions to avoid these risks to their offspring. Such decisions could include the use of donor gametes, preimplantation genetic testing, adoption or opting not to have children.

Another situation is the potential for transmission of an infectious disease to the offspring. For example, if the individual carrying the pregnancy is infected with HIV, hepatitis B, or hepatitis C, there are risks of transmission to the offspring that the other partner may deem too high to proceed with pregnancy were they to be informed of this potential risk.

In some cases, 1 or both partners may have health conditions that they have not disclosed to the other. These may include previous treatment for cancer or for other conditions that have played a role in the need for infertility care. Here, the primary risk is that a partner may undergo the fertility care without knowing that he/she has a greater-thanaverage risk of being left to raise a child on his or her own. In a previous opinion, the Committee has taken the position that it is permissible to provide infertility care to patients with potentially life-limiting illnesses. The Committee wrote: ‘‘Concerns about the welfare of resulting offspring, whether due to an expected shortened lifespan of the parent or effects of cancer or infertility treatment (in the present state of knowledge) ordinarily are not a sufficient reason to deny cancer patients assistance in reproducing’’ (5). This discussion assumed that both partners were aware of the possibility of a partner’s earlier death and voluntarily took on the risk of raising a child alone. Here, where the partner is not disclosing his or her condition, the other may be assuming a risk of raising a child alone that they would prefer to avoid.

There are also situations in which pregnancy is risky to the patient because of an underlying medical condition and the risk of morbidity or mortality is increased over the baseline risk that pregnancy presents. Such cases occur, for example, in a woman with Turner syndrome whose partner may not be aware that carrying a pregnancy is associated with a risk of aortic dissection and death. Knowing this, the partner may have chosen to avoid initiating a pregnancy with her in favor of choosing to create a family with a gestational carrier or via adoption. The lack of disclosure may lead to a situation where he faces the consequences of being a single father because of maternal death. Certainly, such situations also increase the risk of pregnancy and neonatal complications, including preterm birth. Disclosure between intimate partners should be strongly encouraged in these cases.


There are also cases in which a partner does not want to disclose information that could have enabled the couple to avoid the need for some or all infertility treatments. One example is a situation in which the use of anabolic steroids or testosterone leads to a low or absent sperm count, necessitating the use of intrauterine insemination or in vitro fertilization (IVF) that would be otherwise unnecessary. Other scenarios could include an individual who is sterile due to a previous vasectomy or tubal ligation. Individuals may not wish to disclose this information to their partner or to consider the possibility of reversing the vasectomy or the tubal ligation before undergoing fertility treatment. In such cases, disclosure should be strongly encouraged between intimate partners. However, for the affected couple, the only way for conception to occur given the present circumstances is with assisted reproduction, and the parties would be aware of the risks and benefits of fertility treatment. Although, ideally, the information should be shared, clinicians may choose to offer fertility services in the absence of disclosure of the surgical etiology of the infertility. Under these circumstances, partners are aware of the need for assisted reproduction and can be fully counseled regarding the risks of the procedure; they only lack knowledge of the reason why the procedure is needed.

In other cases, a partner may not have disclosed to the other previous sexual abuse, leading to inability to have intercourse. Perhaps psychological treatment could help that individual achieve normal sexual function and avoid the need for fertility treatment. However, the partner in such a case is aware of the existence of the inability to complete intercourse and the need for fertility treatment. Both partners can provide informed consent regarding the proposed treatment modality without breaking the confidentiality of the individual who prefers not to disclose the etiology of the inability to have intercourse. Again, an emphasis on counseling from a trained mental health professional with expertise in the complex psychosocial issues faced by fertility patients should be offered and encouraged.

Another situation in which the patient may not wish to share the etiology of infertility with her partner is in cases of Asherman syndrome due to a previous pregnancy termination. The partner may be morally or otherwise opposed to abortion and would then view his partner differently causing harm to the relationship.


Yet another scenario is a case in which the male partner has a congenital bilateral absence of the vas deferens and his partner has conceived a child that he believes to be genetically his. In the course of a secondary infertility evaluation, the reality that the pregnancy could not have been achieved without assistance will likely become apparent. With the absence of a specific directive by the male patient to withhold relevant findings from the evaluation, the clinician is obligated to fully inform the male of his medical circumstances. This duty holds regardless of whether the male partner inquires if the previous child could be his genetic offspring. This duty to disclose the male’s medical circumstances also holds even when the female partner requests that the physician not reveal the means by which she previously conceived. There is significant concern in such cases that, beyond emotional harm, the woman or child may experience psychological or physical harm or abuse after such disclosures, and great care should be taken by the clinician to be sensitive to this possibility.


Respect for patient confidentiality is a core principle of bioethics. Patient autonomy requires that individuals should be able to choose whether to permit others to know information about their health. Confidentiality also is critical for patients to trust providers and be willing to share information with them. As such, a standard recommendation when patients wish not to disclose information is that confidences should be kept. If there are strong reasons favoring disclosure to prevent harm to the patient or others, the patient should be counseled about the advisability of disclosure. A related recommendation is that if confidentiality cannot be kept (e.g., because of state reporting requirements), the patient should be told this, if at all possible before the information is even obtained. Thus, the recommendation is that patients be counseled about the need for disclosure of positive HIV tests before HIV tests are performed. A further reason for protecting confidentiality is that disclosure may be harmful to the patient if it results in loss of important benefits, damage to relationships, or violence. Confidentiality becomes especially problematic when it is associated with risks to others (6–9).

In the cases outlined earlier, the following risks were identified:
  • The partner may face physical risks due to the potential of disease transmission or the need to undergo procedures that he or she may choose to avoid.
  • The partner may face risks to offspring that he or she may choose to avoid.
  • The partner may face a higher risk of becoming a single parent, when he or she would prefer to remain childless rather than raising a child alone without the other partner.
  • The partner may remain ignorant of the information that he or she would regard as important in the context of the relationship.
  • The patient may face physical or emotional abuse by the partner.
  • Treatment options may be impacted or eliminated.

These risks are of differing strengths when weighed against the importance of confidentiality and reasons supporting nondisclosure.

If a partner faces physical risks from treatment that are not disclosed because of their partner’s insistence on confidentiality, informed consent is not possible. The partner undergoing treatment would face undisclosed but significant risks. In the Committee’s opinion, it would be unethical to provide the treatment under conditions in which informed consent cannot be obtained. The clinician should advise the nondisclosing partner of the importance of disclosure for treatment to proceed. If the nondisclosure is of information that may allow infertility treatment to be avoided, informed consent to infertility treatment is possible; however, informed consent regarding the range of options and the etiology of the infertility is not. Because there is a possibility that the treatment may be avoided, clinicians may ethically decline to provide treatment in such cases.

In the case of risks to offspring, the nondisclosing partner does not face physical risks to himself or herself. However, the other partner has extremely strong interests in knowing about the risks to offspring and participating in decisions about whether to pursue other options. 

In cases in which a patient is at increased risk of negative health effects or pregnancy-related risks resulting from fertility treatment, personal risks may result in the partner being left to raise children on their own. Although there are cases in which such risks are higher than average due to specific medical determinants, such risks are ones that anyone may take in having children. Because the unaware partner has a strong interest in participating in the decision about whether to undertake this risk, clinicians should strongly encourage disclosure (10). Clinicians should also advise the patient that depending on the clinical course, the confidence may be difficult to keep in any event. Assuming that the treatment is permissible in spite of the risks (11), clinicians may provide treatment in these cases, especially if the reasons for nondisclosure are strong. An example would be the possibility of failure of the relationship if the disclosure were made.

If the nondisclosure results in economic costs—the costs of treatment—that may be avoided, disclosure should be encouraged. For example, a female with a previous tubal ligation will require IVF for tubal factor infertility. Knowing the reason for the tubal infertility will not change the need for the treatment. Likewise, a male with a previous vasectomy will need either a vasectomy reversal or sperm extraction and likely IVF. Again, the economic realities are not affected by the etiology of the infertility. In such cases, the partner with incomplete knowledge regarding the cause of the infertility is,  nevertheless, fully aware of the costs and can choose whether to participate in the infertility process. Although disclosure should be encouraged in these cases, it is permissible for the clinician to provide treatment.

In cases in which the nondisclosure is of information that the partner may regard as material to the relationship, such as the effects of a previous abortion, the reasons for nondisclosure are likely extremely strong. Whether to share this information, which is not medically relevant, should be an issue for the partners themselves. Clinicians should provide care in this case and keep the confidence.


Clinicians should encourage partners to share information with one another. Clinicians should refuse to provide care when appropriate informed consent of either partner regarding the proposed treatment may not be assured. Clinicians may refuse to provide care when the explanation of the range of options cannot be fully provided to one of the partners due to the other partner withholding relevant information about the need for the care. When an individual has strong interests in knowledge that his or her partner chooses to withhold, for example, to avoid harm in the offspring or in cases where an increased risk of death or disability from fertility treatment or pregnancy exists, clinicians should strongly encourage disclosure and may decline to provide fertility services. In cases in which disclosure would not change the proposed treatment and the treatment will not cause harm to either the partner or their offspring, clinicians may provide care in the absence of full disclosure between the intimate partners.

Acknowledgments: This report was developed under the direction of the Ethics Committee of the American Society for Reproductive Medicine (ASRM) as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Ethics Committee and Board of Directors of the ASRM have approved this report. This document was reviewed by ASRM members, and their input was considered in the preparation of the final document. The following members of the ASRM Ethics Committee participated in the development of this document: Sigal Klipstein, M.D.; Deborah Anderson; Kavita Shah Arora, M.D., M.B.E.; Tolulope Bakare, M.D.; Katherine Cameron, M.D.; Marcelle Cedars, M.D.; Susan Crockin, J.D.; Ruth Farrell, M.D.; Jessica Goldstein, R.N.; Mandy Katz-Jaffe, Ph.D.; Jennifer Kawwass, M.D.; Joshua Morris, M.D., M.A.; Gwendolyn Quinn, Ph.D.; Robert Rebar, M.D.; Jared Robins, M.D., M.B.A.; Chevis N Shannon, Dr.P.H., M.P.H., M.B.A.; Sean Tipton, M.A.; and Julianne Zweifel, Ph.D. All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. The members of the Committee who were found to have conflicts of interest on the basis of the relationships disclosed did not participate in the discussion or development of this document.


  1. Practice Committee of the American Society for Reproductive Medicine. Practice Committee of the Society for Assisted Reproductive Technology, and Practice Committee of the Society of Reproductive Biologists and Technologists. Minimum standards for practices offering assisted reproductive technologies: a committee opinion. Fertil Steril 2021;115:578–82.
  2. Kreisel KM, Spicknall IH, Gargano JW, Lewis FMT, Lewis RM, Markowitz LE, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex Transm Dis 2021;48:208–14.
  3. Ethics Committee of American Society for Reproductive Medicine. Human immunodeficiency virus (HIV) and infertility treatment: a committee opinion. Fertil Steril 2015;104:e1–8.
  4. Centers for Disease Control and Prevention. Provider information sheet – PrEP during conception, pregnancy, and breastfeeding Pre-Exposure Prophylaxis (PrEP) | HIV Risk and Prevention | HIV/AIDS | CDC. Available at: glish.pdf. Accessed June 12, 2018.
  5. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril 2018;110:380–6.
  6. Adam BD, Corriveau P, Elliott R, Globerman J, English K, Rourke S. HIV disclosure as practice and public policy. Crit Public Health 2015;104:386–97.
  7. HIV basics: just diagnosed, what’s next?, Telling Others About Your HIV Status | Available at: your-status/sexualpartners/. Accessed June 27, 2018.
  8. Kennedy CE, Haberlen S, Amin A, Baggaley R, Narasimha M. Safer disclosure of HIV serostatus for women living with HIV who experience or fear violence: a systematic review. J Int AIDS Soc 2015;18:20292.
  9. Epstein R, Thomas JC, Rutecki GW. Please don’t say anything: partner notification and the patient-physician relationship. Virtual Mentor 2003;5:ccas2–0311.
  10. Ethics Committee of American Society for Reproductive Medicine. Childrearing ability and the provision of fertility services: a committee opinion. Fertil Steril 2013;100:50–3.
  11. Ethics Committee of the American Society for Reproductive Medicine. Provision of fertility services for women at increased risk of complications during fertility treatment or pregnancy: an Ethics Committee opinion. Fertil Steril 2022;117:713–9.

Ethics Opinions

Ethics Committee Reports are drafted by the members of the ASRM Ethics Committee on the tough ethical dilemmas of reproductive medicine.
Ethics Committee teaser

Family members as gamete donors or gestational carriers: an Ethics Committee opinion (2024)

The use of adult intrafamilial gamete donors and gestational surrogates is ethically acceptable when all participants are fully informed and counseled.
Ethics Committee teaser

Financial ‘‘risk-sharing’’ or refund programs in assisted reproduction: an Ethics Committee opinion (2023)

Financial ‘‘risk-sharing’’ fee structures in programs charge patients a higher initial fee but provide reduced fees for subsequent cycles.
Ethics Committee teaser

Planned oocyte cryopreservation to preserve future reproductive potential: an Ethics Committee opinion (2023)

Planned oocyte cryopreservation is an ethically permissible procedure that may help individuals avoid future infertility.
Ethics Committee teaser

Ethical considerations for telemedical delivery of fertility care: an Ethics Committee opinion (2024)

Telemedicine has the potential to increase access to and decrease the cost of care.

More Resources

MAC 2021 teaser
ASRM Academy on the Go

ASRM MAC Tool 2021

The ASRM Müllerian Anomaly Classification 2021 (MAC2021) includes cervical and vaginal anomalies and standardize terminology within an interactive tool format.

View the MAC Tool
EMR Phrases teaser
Practice Guidance

EMR Shared Phrases/Template Library

This resource includes phrases shared by ASRM physician members to provide a template for individuals to create their own EMR phrases.

View the library
Practice Committee Documents teaser

ASRM Practice Documents

These guidelines have been developed by the ASRM Practice Committee to assist physicians with clinical decisions regarding the care of their patients.

View ASRM Practice Documents
Ethics Committee teaser

ASRM Ethics Opinions

Ethics Committee Reports are drafted by the members of the ASRM Ethics Committee on the tough ethical dilemmas of reproductive medicine.

View ASRM Ethics Opinions
Coding Corner general teaser
Practice Guidance

Coding Corner Q & A

The Coding Corner Q & A is a list of previously submitted and answered questions from ASRM members about coding. Answers are available to ASRM Members only.

View the Q & A
Covid-19 teaser
Practice Guidance

COVID-19 Resources

A compendium of ASRM resources concerning the Novel Corona virus (SARS-COV-2) and COVID-19.

View the resources
Couple looking at laptop for online patient education materials

Patient Resources provides a wide range of information related to reproductive health and infertility through patient education fact sheets, infographics, videos, and other resources.

View Website

Topic Resources

View more on the topic of infertility
Podcast Icon

Fertility and Sterility On Air - Seminal Article: Ernest Ng, and Zhi Chen

June issue Seminal Contribution: a randomized controlled trial studying the use of progestins for ovulation supression in predicted high responders.  Listen to the Episode
Webinars Icon

Aug 15, 2024, 3:00PM CT - Fever Pitch – Startups that are improving access to fertility care

This webinar aims to help identify what factors in fertility-related startups may improve access and equity in reproductive care.

Register For The Webinar
Webinars Icon

Aug 2, 2024, 7:30 AM CT - Psychosocial Care in Fertility Treatment - International Perspectives

Panelists will discuss assessing the degree of distress in couples undergoing infertility treatment and addressing their psychosocial needs.

Register for the Webinar
PR Bulletin Icon

ASRM announces support for HOPE with Fertility Services Act

The American Society for Reproductive Medicine is proud to endorse the HOPE with Fertility Services Act (HR 8821).

View the Press Release
Coding Icon

HyCoSy and CPT 74740

When Office HSG/HyCoSy is performed but no x-ray/fluoroscopic imaging is performed, only ultrasound is done, is it appropriate to bill CPT code 74740? View the Answer
Document Icon

Subclinical hypothyroidism in the infertile female population: a guideline (2024)

This guideline reviews the risks and benefits of treating subclinical hypothyroidism in female patients with a history of infertility and miscarriage. View the Committee Guideline
PR Bulletin Icon

Survey shows strong support for increased access to fertility treatments

A new public opinion poll reveals strong support for improved access to In Vitro Fertilization (IVF). 

View the Press Release
News Icon

Infertility Awareness

In honor of National Infertility Awareness Week (NIAW), we have rounded up some of our resources on infertility. View infertility resources
News Icon

Leave Your Mark! NIAW April 21-27

National Infertility Awareness Week Action Round-Up Click here to leave your mark during NIAW2024
PR Bulletin Icon

National Infertility Awareness Week 2024: Leave Your Mark

Next week is National Infertility Awareness Week, a federally recognized health observance founded to increase awareness of infertility.

View the Press Release
Document Icon

Tobacco or marijuana use and infertility: a committee opinion (2023)

In the United States, approximately 21% of adults report some form of tobacco use, although 18% report marijuana use. View Committee Opinion
Videos Icon

Journal Club Global: The future of REI Fellowship training: debating opportunities and threats

This exciting collaboration discusses the controversy and future directions for the field of Reproductive Endocrinology and Infertility medicine. View the Video
Videos Icon

Journal Club Global: Infertility and Subclinical Hypothyroidism

The impact of treating SCH on fertility, obstetric outcomes, and offspring neurocognitive development is debated in the literature. View the Video
Announcement Icon

ASRM reacts to Alabama legislation

We are pleased that the legislation passed into law by the Alabama General Assembly will at least allow our members in the state to care for their patients.

View the Press Release
Announcement Icon

IVF at the SOTU: Fertility care expected to be major focus at State of the Union

Protecting access to IVF care is expected to be a major theme of the State of the Union on Thursday.

View the Press Release
Document Icon

Ethical considerations for telemedical delivery of fertility care: an Ethics Committee opinion (2024)

Telemedicine has the potential to increase access to and decrease the cost of care. View the Committee Opinion
Announcement Icon

ASRM Responds to Proposed Alabama Legislation

We are proud of our Alabama members and their patients, who have been such incredible advocates working to motivate their legislators to protect IVF.

View the Press Release
Announcement Icon

Senate Budget Hearing is Well Timed Following Alabama IVF Ruling

ASRM statement regarding the Senate Budget Committee’s hearing entitled: No Rights to Speak of: The Economic Harms of Restricting Reproductive Freedom.

View the Press Release
Announcement Icon

ASRM Responds to Senate’s Failure to Pass Access to Family Building Act

We are disappointed by the Senate’s failure to meet the moment and pass federal legislation protecting access to in vitro fertilization (IVF).

View the Press Release
News Icon

What's New from the Fertility and Sterility Family of Journals

Here’s a peek at this month’s issues from our family of journals! As an ASRM Member, you can access all of our journals.
Read More about the newest articles
Announcement Icon

ASRM Condemns Profoundly Misguided and Dangerous Court Decision in Alabama

In LePage v Mobile Infirmary Clinic, the Alabama Supreme Court made a decision that flies in the face of medical reality and the needs of the citizens.

View the Press Release
News Icon

NEW from ASRM Academy: Basic Infertility for Healthcare Providers

ASRM is proud to introduce our updated course: Basic Infertility for Healthcare Providers.  Learn more with an overview from Instructional Designer, Harriet Smith, MEd
News Icon

What's New from the Fertility and Sterility Family of Journals

Here’s a peek at this month’s issues from our family of journals! As an ASRM Member, you can access all of our journals. Not yet a member? Click here(no link) to learn more. Find More
Announcement Icon

ASRM applauds introduction of Access to Family Building Act of 2024

ASRM is thrilled by the introduction of the Access to Family Building Act 

View the Press Release
News Icon

Resource Roundup: Thyroid Health

January is Thyroid Health Awareness Month! View the resource roundup!
Document Icon

Definition of infertility: a committee opinion (2023)

‘‘Infertility’’ is a disease, condition, or status characterized by several factors. View the Committee Opinion
Document Icon

Diagnostic evaluation of sexual dysfunction in the male partner in the setting of infertility: a committee opinion (2023)

It is the responsibility of the clinician to assess for erectile dysfunction, ejaculatory dysfunction, or diminished libido in men presenting for infertility. View the Committee Opinion
Videos Icon

Journal Club Global - Actualización en la suplementación con progesterona en fase lútea para transferencias de embriones congelados

Efectividad del rescate de progesterona en mujeres que presentan niveles bajos de progesterona circulante alrededor del día de la transferencia de embriones View the Video
Document Icon

Endometriosis and infertility: a committee opinion (2012)

Women with endometriosis typically present with pelvic pain, infertility, or an adnexal mass, and may require surgery. View the Committee Opinion
Document Icon

The International Glossary on Infertility and Fertility Care, 2017†‡§ (2017)

Terms and definitions currently used infertility care, infertility and medically assisted reproduction (MAR) can have different meanings that are dependent upon the setting, their usage in research or clinical interventions, or among diverse populations.
View the Committee Joint Guideline
Coding Icon

Surgery Coding

I took the ASRM coding course, and in that course, coding for bilateral neosalpingostomies was coded using only a dx of N70.11 (hydrosalpinx). View the Answer
Coding Icon

Post Vasectomy Infertility

If a husband has had a vasectomy, does the sterilization code apply to the wife's visits? View the Answer
Coding Icon

Pregnancy Of Uncertain Viability Ultrasound

My staff is telling me that I am getting reimbursed for the first sonogram and OB visit (using ICD 10 code for pregnancy of uncertain viability – O36.80X0. View the Answer
Coding Icon

Pregnancy Ultrasound

Our practice does routine ultrasounds (sac check- 76817) at the end of an IVF cycle and bill with a diagnosis code O09.081, pregnancy resulting from ART.  View the Answer
Coding Icon

Self-referred New Patient

A patient self-refers to our physician for an initial new patient consultation instead of referred by another physician, how do we code for the consult? View the Answer
Coding Icon

Telephone Consult

Does a physician need to speak directly to a patient to code for a telephone consult (99371-99373) or can a staff member relay physician notes to patients? View the Answer
Coding Icon

Testing With No History of Infertility

What diagnosis codes should  providers submit to insurance carriers while trying to evaluate fertility issues? View the Answer
Coding Icon

Psychological Evaluation

Many REs require patients (and their spouses/partners) who are considering using donor gametes to see an infertility counselor first. View the Answer
Coding Icon


Should other ovarian dysfunction (diagnosis code E28.8) or unspecified ovarian dysfunction (diagnosis code E28.9) can be used for an IUI or an IVF cycle View the Answer
Coding Icon

Infertility Consult

Does ASRM have any examples of evaluation and management documentation for patients being seen for an initial infertility evaluation? View the Answer
Coding Icon

Infertility Consult by Nurse

What code is used for a nurse practitioner seeing a fertility patient for the first time? View the Answer
Coding Icon

Initial Visit for Infertility With No Mandated Coverage

What code would be appropriate for an initial visit for infertility?  View the Answer
Coding Icon

Monitoring E&M

Our group would like to know if others are billing an evaluation and management code for ultrasound and blood draw visits? View the Answer
Coding Icon

New vs Established Patient

How soon can you bill as a new infertility patient? View the Answer
Coding Icon

Hysteroscopy Recurrent Implantation Failure

What is the appropriate ICD-10 code for recurrent implantation failure?  View the Answer
Coding Icon

General E&M Consult

Recently we have received a “re-code” on a new patient (we billed a 99203 and the insurance re-coded it to a 99213).  View the Answer
Coding Icon

D&C Under Ultrasound Guidance

What are the CPT codes and ICD-10 codes for coding a surgical case for a patient with history of Stage B adenocarcinoma of the cervix ... View the Answer
Coding Icon

Diagnosis of Infertility for IVF Procedure

How important is it to have accurate documentation of the type of infertility diagnosis for IVF procedures?  View the Answer
Coding Icon

Diagnostic Testing of an Infertile Couple

The Z31.41 is or is not the correct code to use for diagnostic testing of an infertile couple? And If so can if be used as the primary and only code? View the Answer
Coding Icon

Blood Draws

If a patient comes in only for a blood draw (venipuncture) and is seen only by the lab technician (not an MD, PA, or NP), may we bill for a (minimal) office visit? View the Answer
Coding Icon

Blood Tests

Patients are requesting to have lab work drawn from the female patient moved to the males account due to the female fertility coverage being maxed out.  View the Answer
Coding Icon

Male Infertility

A summary of common codes for Male Infertility compiled by the ASRM Coding Committee. View the Coding Summary
Document Icon

ASRM müllerian anomalies classification 2021

The Task Force set goals for a new classification and chose to base it on the iconic AFS classification from 1988 because of its simplicity and recognizability. View the Committee Opinion
Document Icon

Intracytoplasmic sperm injection (ICSI) for non–male factor indications: a committee opinion (2020)

Intracytoplasmic sperm injection is frequently used in combination with assisted reproductive technologies. View the Committee Document
Document Icon

Moving innovation to practice: an Ethics Committee opinion (2021)

The introduction of new strategies, tests, and procedures into clinical practice raises challenging ethical issues. View the Committee Opinion
Document Icon

Fertility evaluation of infertile women: a committee opinion (2021)

Diagnostic evaluation for infertility in women should be conducted in a systematic, expeditious, and cost-effective manner. View the Committee Opinion
Document Icon

Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion (2019)

The Ethics Committee recommends that in vitro fertilization (IVF) centers develop patient-centered policies regarding requests for futile treatment.  View the Committee Opinion
Document Icon

Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion (2020)

Pretreatment evaluation, indications, treatment regimens, and complications of gonadotropin treatment. View the Committee Opinion
Document Icon

Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review (2019)

Providers who care for women at risk for hereditary gynecologic cancers must consider the impact of these conditions. View the Joint Statement
Document Icon

Guidance for Providers Caring for Women and Men Of Reproductive Age with Possible Zika Virus Exposure (Updated 2019)

This ASRM guidance specifically addresses Zika virus infection issues and concerns of individuals undergoing assisted reproductive technologies (ART). View the Guideline
Document Icon

American Society for Reproductive Medicine position statement on uterus transplantation: a committee opinion (2018)

Following the birth of the first child from a transplanted uterus in Gothenburg, Sweden, in 2014, other centers worldwide have produced scientific reports. View the Committee Opinion
Document Icon

Child-rearing ability and the provision of fertility services: an Ethics Committee opinion (2017)

Fertility programs may withhold services on the basis that patients will be unable to provide minimally adequate or safe care for offspring. View the Committee Opinion
Document Icon

Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline (2017)

This review evaluates if uterine myomas impact likelihood of pregnancy and pregnancy loss, and if myomectomy influences pregnancy outcomes. View the Guideline
Document Icon

Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement (2014)

Clinical trials testing infertility treatments often do not report on the major outcomes of interest to patients and clinicians and the public. View the Guideline